INTEGRATION OF DIAGNOSTICS AND MONITORING OF THERAPY IN PATIENTS WITH CMV INFECTION
Article Sidebar
Main Article Content
Abstract
This article is dedicated to the integration of diagnostics and therapy monitoring in patients with cytomegalovirus (CMV) infection. In immunocompromised individuals, particularly recipients of solid organ and hematopoietic stem cell transplantation, CMV can cause severe morbidity and mortality. The article reviews the importance of combining modern diagnostic methods (such as quantitative PCR) with systematic monitoring to enable early detection of CMV replication, timely initiation of preemptive therapy, personalization of treatment duration, and identification of antiviral drug resistance. The primary diagnostic and monitoring methods, the results of their application, and the benefits of an integrated approach for optimizing patient outcomes are analyzed based on the IMRAD (Introduction, Methods, Results, and Discussion) structure. It is emphasized that this strategy significantly reduces CMV-related complications and increases treatment efficacy.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
How to Cite
References
1.American Society of Transplantation Infectious Diseases Community of Practice. (2019). Cytomegalovirus in solid organ transplantation. American Journal of Transplantation, 19(S2), 1-61.
2.Campos-Varela, I., & Ljungman, P. (2021). Cytomegalovirus infection in hematopoietic cell transplantation. Blood Reviews, 46, 100742.
3.Fishman, J. A. (2017). A paradigm for the management of cytomegalovirus in solid-organ transplant recipients. Transplant Infectious Disease, 19(5), e12745.
4.Kotton, C. N., Kumar, D., Caliendo, A. M., Huprikar, S., Chou, S., Danziger-Isakov, L., & Humar, A. (2018). The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation, 102(6), 900-931.
5.Ljungman, P., de la Camara, R., Robin, C., Crocchiolo, R., Einsele, H., Hill, J. A., ... & Cordonnier, C. (2019). Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). The Lancet Infectious Diseases, 19(8), e260-e272.
6.Pescovitz, M. D., Rabkin, J., & Merion, R. M. (2014). The role of viral load in the diagnosis and management of cytomegalovirus infection after solid organ transplantation. American Journal of Transplantation, 14(S4), 1-13.
7.Styczynski, J. (2018). How I treat refractory/resistant cytomegalovirus infection in hematopoietic cell transplant recipients. Blood, 131(14), 1545-1553.